Michelle Robinson obtained her PhD from the University of Texas at Austin where she developed ultraviolet photodissociation mass spectrometry as a tool for sequencing peptides and mapping their post-translational modifications. After graduation she started her career at Merck as a post-doctoral fellow applying targeted proteomics approaches for biomarker discovery. In her current role as Associate Principal Scientist in Merck’s Discovery Bioanalytics group, she is responsible for developing LC-MS assays to quantify protein therapeutics, biomarkers, and endogenous targets to support preclinical PK/PD and target engagement measurements.